The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 29, 2017

Filed:

Mar. 15, 2013
Applicant:

Yale University, New Haven, CT (US);

Inventors:

David Spiegel, New Haven, CT (US);

Christopher Parker, Medina, OH (US);

Assignee:

YALE UNIVERSITY, New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); C07H 15/26 (2006.01); A61K 45/06 (2006.01); A61K 31/67 (2006.01); A61K 31/706 (2006.01); C07D 405/14 (2006.01); A61K 47/48 (2006.01); A61K 31/704 (2006.01); A61K 31/7028 (2006.01); A61K 31/7034 (2006.01);
U.S. Cl.
CPC ...
C07H 15/26 (2013.01); A61K 31/67 (2013.01); A61K 31/706 (2013.01); A61K 45/06 (2013.01); A61K 47/481 (2013.01); A61K 47/48215 (2013.01); C07D 405/14 (2013.01); A61K 31/704 (2013.01); A61K 31/7028 (2013.01); A61K 31/7034 (2013.01);
Abstract

The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as CDM-Hs, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by introducing cytotoxic moieties to gp120-expressing cells, thereby causing cell death and preventing cell infection and spread of HIV. It is shown that CDM-Hs bind to gp120 and gp-120 expressing cells competitively with CD4, and these compounds cause cell death of HIV-infected cells, thereby decreasing viral infectivity. Compounds and methods are described herein.


Find Patent Forward Citations

Loading…